| Autor: |
Li, Ying, Guo, Fanxi, Jiang, Xiangyuan, Ren, Juncai, Miao, Yingxue, Ding, Fangyi, Yu, Zugong |
| Předmět: |
|
| Zdroj: |
Journal of Veterinary Pharmacology & Therapeutics; Mar2020, Vol. 43 Issue 2, p189-196, 8p |
| Abstrakt: |
This study aimed to develop one novel meloxicam (MEL) oil suspension for sustained‐release and compare the pharmacokinetic characteristics of it with MEL conventional formulation in pigs after a single intramuscular administration. Six healthy pigs were used for the study by a crossover design in two periods with a withdrawal interval of 14 days. Plasma concentrations of MEL were measured by ultra‐performance liquid chromatography–tandem mass spectrometry (UPLC‐MS/MS). Pharmacokinetic parameters were calculated by noncompartmental methods. The difference was statistically significant (p <.05) between MEL oil suspension and MEL conventional formulation in pharmacokinetic parameters of mean residence time (6.16 ± 4.04) hr versus (2.66 ± 0.55) hr, peak plasma concentration (Cmax) (0.82 ± 0.12) µg/ml versus (1.12 ± 0.22) µg/ml, time needed to reach Cmax (Tmax) (2.33 ± 0.82) hr versus (0.59 ± 0.18) hr, and terminal elimination half‐life (t1/2λz) (3.74 ± 2.66) hr versus (1.55 ± 0.37) hr. The mean area under the concentration–time curve (AUC0–∝) of MEL oil suspension and MEL conventional formulation was 5.35 and 3.43 hr µg/ml, respectively, with a relative bioavailability of 155.98%. Results of the present study demonstrated that the MEL oil suspension could prolong the effective time of drugs in blood, thereby reducing the frequency of administration on a course of treatment. Therefore, the novel MEL oil suspension seems to be of great value in veterinary clinical application. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text